[
  {
    "ts": null,
    "headline": "The beginning of the end: Eliquis sales forecast to plummet as EU patent expiry nears",
    "summary": "The BMS-Pfizer alliance has dominated the anticoagulant drug market, earning approximately $82.6bn in revenue since 2011.",
    "url": "https://finnhub.io/api/news?id=b8f56076e94d31e105791c98b9b1fa8643e7517866008137342159322c976aca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769615340,
      "headline": "The beginning of the end: Eliquis sales forecast to plummet as EU patent expiry nears",
      "id": 138285224,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The BMS-Pfizer alliance has dominated the anticoagulant drug market, earning approximately $82.6bn in revenue since 2011.",
      "url": "https://finnhub.io/api/news?id=b8f56076e94d31e105791c98b9b1fa8643e7517866008137342159322c976aca"
    }
  },
  {
    "ts": null,
    "headline": "Bleeding Disorders Treatment Global Market Review 2021-2025 and Forecast 2026-2031 Featuring Profiles of Takeda Pharmaceutical Co., Roche, Novo Nordisk, Pfizer, Bayer and More",
    "summary": "The bleeding disorders treatment market is expanding due to increased diagnosis rates and government support, with significant growth driven by gene therapies and extended-half-life products. However, high treatment costs hinder accessibility in low-income regions, causing disparity in global healthcare access. Bleeding Disorders Treatment Market Bleeding Disorders Treatment Market Dublin, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The \"Bleeding Disorders Treatment Market - Global Industry Size, Share, T",
    "url": "https://finnhub.io/api/news?id=ecb6e5f0568edfb7d85ac3741a8f0640fde24033ecf960898454f2955406bd72",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769614560,
      "headline": "Bleeding Disorders Treatment Global Market Review 2021-2025 and Forecast 2026-2031 Featuring Profiles of Takeda Pharmaceutical Co., Roche, Novo Nordisk, Pfizer, Bayer and More",
      "id": 138281597,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The bleeding disorders treatment market is expanding due to increased diagnosis rates and government support, with significant growth driven by gene therapies and extended-half-life products. However, high treatment costs hinder accessibility in low-income regions, causing disparity in global healthcare access. Bleeding Disorders Treatment Market Bleeding Disorders Treatment Market Dublin, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The \"Bleeding Disorders Treatment Market - Global Industry Size, Share, T",
      "url": "https://finnhub.io/api/news?id=ecb6e5f0568edfb7d85ac3741a8f0640fde24033ecf960898454f2955406bd72"
    }
  },
  {
    "ts": null,
    "headline": "Some of Pharma's Biggest Brands Face a New Reality",
    "summary": "A government process quietly moves forward",
    "url": "https://finnhub.io/api/news?id=48ae2d909b1bce31a2977fa3cc46c5767b5b75f264a8467010fbce54b699fc3f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769611689,
      "headline": "Some of Pharma's Biggest Brands Face a New Reality",
      "id": 138281443,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "A government process quietly moves forward",
      "url": "https://finnhub.io/api/news?id=48ae2d909b1bce31a2977fa3cc46c5767b5b75f264a8467010fbce54b699fc3f"
    }
  },
  {
    "ts": null,
    "headline": "TransCelerate BioPharma Showcases Approaches to Advancing Clinical Trial Efficiency and Patient-Centered Design at SCOPE US 2026",
    "summary": "TransCelerate BioPharma (TransCelerate), a nonprofit organization dedicated to improving the health of people around the world by accelerating and simplifying clinical research, will highlight practical, scalable approaches to advancing more efficient, patient-centered clinical trials across the research lifecycle at SCOPE Summit 2026, taking place February 2-5 in Orlando, Florida.",
    "url": "https://finnhub.io/api/news?id=c1a992498f9bac0f92cd284cfde5062818544c1b6f16c27d4322f94e119479f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769607000,
      "headline": "TransCelerate BioPharma Showcases Approaches to Advancing Clinical Trial Efficiency and Patient-Centered Design at SCOPE US 2026",
      "id": 138280643,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "TransCelerate BioPharma (TransCelerate), a nonprofit organization dedicated to improving the health of people around the world by accelerating and simplifying clinical research, will highlight practical, scalable approaches to advancing more efficient, patient-centered clinical trials across the research lifecycle at SCOPE Summit 2026, taking place February 2-5 in Orlando, Florida.",
      "url": "https://finnhub.io/api/news?id=c1a992498f9bac0f92cd284cfde5062818544c1b6f16c27d4322f94e119479f2"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Reshapes Portfolio As ViiV Exit Meets White House Pricing Deal",
    "summary": "Pfizer is exiting its HIV-focused joint venture, ViiV Healthcare, while reshaping its portfolio around other therapeutic areas. The company has reached a significant agreement with the White House that trades tariff relief for reduced drug pricing in the U.S. Pfizer is advancing late-stage drugs in its pipeline and has signed a non-exclusive licensing deal with Novavax for Matrix-M vaccine adjuvant technology. Pfizer (NYSE:PFE) is making several moves at once, shifting away from the ViiV...",
    "url": "https://finnhub.io/api/news?id=0eb567d8f90ee17dfc8876ce9a95043a5118d16f2fd31a3701ccb5651e0a670d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769606339,
      "headline": "Pfizer Reshapes Portfolio As ViiV Exit Meets White House Pricing Deal",
      "id": 138280732,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer is exiting its HIV-focused joint venture, ViiV Healthcare, while reshaping its portfolio around other therapeutic areas. The company has reached a significant agreement with the White House that trades tariff relief for reduced drug pricing in the U.S. Pfizer is advancing late-stage drugs in its pipeline and has signed a non-exclusive licensing deal with Novavax for Matrix-M vaccine adjuvant technology. Pfizer (NYSE:PFE) is making several moves at once, shifting away from the ViiV...",
      "url": "https://finnhub.io/api/news?id=0eb567d8f90ee17dfc8876ce9a95043a5118d16f2fd31a3701ccb5651e0a670d"
    }
  },
  {
    "ts": null,
    "headline": "CMS selects next batch of 15 high-cost medicines for third negotiation cycle",
    "summary": "The 15 drugs accounted for $27bn in spending via Medicare Part B and Part D between November 2024 and October 2025.",
    "url": "https://finnhub.io/api/news?id=1934eea251c629d11b9eedf631f389a3683800a20c7fd83d6320c306aa3c8579",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769604538,
      "headline": "CMS selects next batch of 15 high-cost medicines for third negotiation cycle",
      "id": 138280575,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The 15 drugs accounted for $27bn in spending via Medicare Part B and Part D between November 2024 and October 2025.",
      "url": "https://finnhub.io/api/news?id=1934eea251c629d11b9eedf631f389a3683800a20c7fd83d6320c306aa3c8579"
    }
  },
  {
    "ts": null,
    "headline": "Healthy Returns: Botox, Trulicity among 15 drugs added to Medicare price negotiations",
    "summary": "The Trump administration kicked off another round of Medicare drug price negotiations, while Kaiser Permanente agrees to pay a historic settlement.",
    "url": "https://finnhub.io/api/news?id=5ae77557973ed9453fe5371e6a9ab2b8b579680df212327413d4e8b25d81b98e",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769602052,
      "headline": "Healthy Returns: Botox, Trulicity among 15 drugs added to Medicare price negotiations",
      "id": 138282758,
      "image": "https://image.cnbcfm.com/api/v1/image/107188275-16753645842023-02-02t183236z_737430976_rc253z9n9jw3_rtrmadp_0_lilly-results.jpeg?v=1694350801&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "The Trump administration kicked off another round of Medicare drug price negotiations, while Kaiser Permanente agrees to pay a historic settlement. ",
      "url": "https://finnhub.io/api/news?id=5ae77557973ed9453fe5371e6a9ab2b8b579680df212327413d4e8b25d81b98e"
    }
  },
  {
    "ts": null,
    "headline": "Global Glioma Market Growth Driven by Therapeutic Innovations and Aging Population",
    "summary": "The Global Glioma Market is focused on managing gliomas, aggressive brain tumors from glial cells. Glioblastoma Multiforme (GBM) is the deadliest type, characterized by rapid growth and invasiveness. Early diagnosis and treatment are crucial for improving patient outcomes. The market is driven by rising glioma cases, advancing cancer therapies, and enhanced diagnostic tools. Challenges include drug resistance, high treatment costs, and complex regulatory issues. Leading companies like Merck & Co",
    "url": "https://finnhub.io/api/news?id=be844d19e718dbc24b1c5f2029e9c25e198fe1cc276b66d02030ff0c0856a114",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769601840,
      "headline": "Global Glioma Market Growth Driven by Therapeutic Innovations and Aging Population",
      "id": 138280644,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Global Glioma Market is focused on managing gliomas, aggressive brain tumors from glial cells. Glioblastoma Multiforme (GBM) is the deadliest type, characterized by rapid growth and invasiveness. Early diagnosis and treatment are crucial for improving patient outcomes. The market is driven by rising glioma cases, advancing cancer therapies, and enhanced diagnostic tools. Challenges include drug resistance, high treatment costs, and complex regulatory issues. Leading companies like Merck & Co",
      "url": "https://finnhub.io/api/news?id=be844d19e718dbc24b1c5f2029e9c25e198fe1cc276b66d02030ff0c0856a114"
    }
  },
  {
    "ts": null,
    "headline": "Has Novavax cracked the code for survival in the vaccine arena?",
    "summary": "The company’s new partnership with Pfizer is worth up to $530 million — and could be just the beginning.",
    "url": "https://finnhub.io/api/news?id=19916f1b1316e96be52dd98656f83d8ca5836df6be9942372c685889dd01657b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769587200,
      "headline": "Has Novavax cracked the code for survival in the vaccine arena?",
      "id": 138280735,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The company’s new partnership with Pfizer is worth up to $530 million — and could be just the beginning.",
      "url": "https://finnhub.io/api/news?id=19916f1b1316e96be52dd98656f83d8ca5836df6be9942372c685889dd01657b"
    }
  }
]